Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUNK59)

• Drug Name: Bafilomycin A1 Drug Info
• Synonyms: bafilomycin A1; 88899-55-2; MFCD06795130; CHEMBL290814; CHEBI:22689; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-{(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyltetrahydro-2H-pyran-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one; Bafilomycin; NSC381866; Bafilomycin A1/; Hygrolidin, 21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-; Bafilomycin A1 from Streptomyces griseus; BSPBio_001470; MEGxm0_000385; SCHEMBL13775181; ACon0_000813; HMS3402J12; Bafilomycin A1 Ready Made Solution; ABP000610; BDBM50064186; AKOS030213158; ZINC169647947; DB06733; MCULE-2359469972; NCGC00163426-02; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one; Q4841341; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyl-tetrahydropyran-2-yl]-2-hydroxy-1-methyl-butyl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
• Cross-matching ID:
  PubChem CID: 6436223
  ChEBI ID: CHEMBL290814
  CAS Number: CAS 88899-55-2
  TTD Drug ID: D4VBY6

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.75	0.00e+0	19/20 (95%)	MSMO1;SQLE;FDFT1;...
Terpenoid backbone biosynthesis	2.20	0.00e+0	18/22 (81.82%)	HMGCS1;IDI1;ACAT2;...
Vibrio cholerae infection	2.08	0.00e+0	44/50 (88%)	TJP2;ATP6AP1;ATP6V1D;...
Amino sugar and nucleotide sugar metabolism	1.93	8.63e-3	38/48 (79.17%)	HK2;NAGK;GNE;...
AMPK signaling pathway	1.92	6.90e-3	106/120 (88.33%)	SCD;HMGCR;PFKL;...
mTOR signaling pathway	1.89	7.67e-3	114/154 (74.03%)	DEPTOR;KRAS;ATP6V1D;...
Synthesis and degradation of ketone bodies	1.87	6.57e-3	9/10 (90%)	HMGCS1;ACAT2;HMGCS2
Collecting duct acid secretion	1.87	7.19e-3	22/27 (81.48%)	ATP6V1D;ATP6V1F;ATP6V1C1;...
Glycolysis / Gluconeogenesis	1.86	6.39e-3	56/67 (83.58%)	ENO2;PKM;PFKL;...
Adipocytokine signaling pathway	1.85	8.05e-3	64/69 (92.75%)	RXRA;ACSL1;SLC2A1;...
Autophagy	1.83	8.37e-3	113/169 (66.86%)	DEPTOR;DAPK1;KRAS;...
Synaptic vesicle cycle	1.83	7.67e-3	63/78 (80.77%)	SYT1;ATP6V1D;ATP6V1F;...
Glucagon signaling pathway	1.80	9.73e-3	89/107 (83.18%)	PKM;PFKL;FBP1;...
Inositol phosphate metabolism	1.79	1.15e-2	66/73 (90.41%)	IMPA2;SYNJ2;CDIPT;...
Ovarian steroidogenesis	1.78	1.23e-2	41/51 (80.39%)	LDLR;ADCY1;HSD17B7;...
PPAR signaling pathway	1.77	1.29e-2	66/74 (89.19%)	SCD;HMGCS1;FADS2;...
Insulin signaling pathway	1.77	1.35e-2	121/137 (88.32%)	FBP1;KRAS;ACACA;...
Cortisol synthesis and secretion	1.75	1.66e-2	58/65 (89.23%)	PBX1;LDLR;ADCY1;...
Pantothenate and CoA biosynthesis	1.75	1.57e-2	14/21 (66.67%)	BCAT1;PANK3;ENPP1;...
Starch and sucrose metabolism	1.75	1.50e-2	25/36 (69.44%)	ENPP1;HK2;GYG1;...
Insulin resistance	1.71	2.52e-2	96/108 (88.89%)	SLC27A2;SLC2A1;AKT1;...
Biosynthesis of unsaturated fatty acids	1.70	2.67e-2	21/27 (77.78%)	SCD;FADS1;FADS2;...
Longevity regulating pathway	1.66	4.00e-2	90/151 (59.6%)	KRAS;ADCY1;AKT1;...
Mitophagy	1.65	4.03e-2	56/68 (82.35%)	KRAS;BNIP3L;BNIP3;...
Phosphatidylinositol signaling system	1.65	4.10e-2	82/97 (84.54%)	IMPA2;SYNJ2;CDIPT;...
Mucin type O-glycan biosynthesis	1.64	4.16e-2	20/36 (55.56%)	GALNT14;GALNT7;GALNT11;...
Fructose and mannose metabolism	1.63	4.60e-2	30/33 (90.91%)	PFKL;FBP1;HK2;...
Autoimmune thyroid disease	-1.69	4.31e-2	46/53 (86.79%)	IL10;IFNA6;IFNA2;...
Basal cell carcinoma	-1.73	3.12e-2	41/63 (65.08%)	FZD3;TP53;GSK3B;...
Intestinal immune network for IgA production	-1.84	8.41e-3	38/48 (79.17%)	AICDA;MADCAM1;CD80;...
Complement and coagulation cascades	-1.88	5.05e-3	76/85 (89.41%)	SERPINB2;C5AR1;CR2;...
Systemic lupus erythematosus	-1.95	2.10e-3	45/135 (33.33%)	FCGR2A;HLA-DRB1;C1QB;...
Mineral absorption	-1.97	2.80e-3	48/60 (80%)	ATP1B3;SLC39A4;ATP1B1;...
Staphylococcus aureus infection	-1.98	4.21e-3	72/95 (75.79%)	FCGR2A;C5AR1;HLA-DRB1;...
Spliceosome	-2.20	0.00e+0	101/150 (67.33%)	CDC5L;EIF4A3;PPIE;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.05uM	6H	Hide ▲

Fibroblast

Nasopharyngeal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
FIBRNPC	CVCL_UK07	Homo sapiens	1.11uM - 10uM	6H, 24H	Hide ▲

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.05uM	6H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.05uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.05uM	6H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.05uM	6H	Show ▼